• June 16-19, 2025
  • Boston Convention & Exhibition Center

AaviGen

Loading

AaviGen

Tuesday, June 04, 2024
Company Presentation
Cell and Gene Therapy and Genome Editing
Company Presentation Theater 4
Founded in 2019, AaviGen GmbH is a pre-clinical stage biotechnology company specializing in the development of transformative gene therapy medicinal products (GTMPs) for genetic and acquired cardiovascular and cardiopulmonary diseases. By leveraging a proprietary portfolio of genetically-engineered heart-specific Adeno-Associated Viruses (AAVs) to deliver therapeutic genes directly to the diseased heart cells via a single intravenous injection, AaviGen’s mission is to advance safe and effective precision GTMPs for heart-related ailments. Integrating cutting-edge technologies with the interdisciplinary expertise of its founders – spanning clinical cardiology, virology and genetic vector engineering, GTMP development, health economics and regulatory affairs – AaviGen strives to address the unmet needs of millions of patients worldwide with its scalable vector platform and therapeutic pipeline, ultimately reshaping the clinical landscape of cardiovascular care.
AaviGen
Company Website: https://aavigen.com
Lead Product in Development: Heart-specific AAV-based GTMP against congestive heart failure improving cardiac contractile performance and energy metabolism and reversing arrhythmia propensity and maladaptive growth of the failing heart.
Number Of Unlicensed Products (For Which You Are Seeking Partners): 2-4

Company HQ City

Heidelberg

Company HQ State

Baden-Württemberg

Company HQ Country

Germany

CEO/Top Company Official

Prof. Dr. Patrick Most

Development Phase of Primary Product

Pre-Clinical
Speakers
Patrick Most
CEO
AaviGen
Back to Session List

BIO DOUBLE HELIX SPONSORS

Thanks to our sponsors for supporting our mission to drive a revolution to cure patients, protect our climate, and nourish humanity.

Loading

BIO HELIX SPONSORS